Nautilus Biotechnology, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own8.00% Shs Outstand124.42M Perf Week-10.83%
Market Cap345.10M Forward P/E- EPS next Y-0.90 Insider Trans1.03% Shs Float90.31M Perf Month-18.94%
Income-57.70M PEG- EPS next Q-0.17 Inst Own45.30% Short Float2.40% Perf Quarter-34.76%
Sales- P/S- EPS this Y-221.60% Inst Trans27.95% Short Ratio5.79 Perf Half Y-53.64%
Book/sh2.81 P/B0.95 EPS next Y-30.90% ROA-14.80% Target Price8.00 Perf Year-73.28%
Cash/sh2.51 P/C1.06 EPS next 5Y- ROE-15.60% 52W Range2.55 - 12.38 Perf YTD-48.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.39% Beta-
Dividend %- Quick Ratio51.10 Sales past 5Y- Gross Margin- 52W Low4.90% ATR0.26
Employees113 Current Ratio51.10 Sales Q/Q- Oper. Margin- RSI (14)35.67 Volatility10.75% 8.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-87.00% Profit Margin- Rel Volume0.43 Prev Close2.77
ShortableYes LT Debt/Eq0.00 EarningsMay 03 BMO Payout- Avg Volume374.87K Price2.67
Recom2.20 SMA20-16.31% SMA50-27.01% SMA200-41.91% Volume162,251 Change-3.43%
Jan-06-22Initiated Morgan Stanley Equal-Weight $8
Nov-02-21Initiated Cowen Outperform
Aug-04-21Initiated Goldman Neutral $10
Jul-13-21Initiated Jefferies Buy $13
May-12-22 06:28AM  
May-03-22 06:00AM  
Apr-12-22 08:00AM  
Apr-07-22 08:00AM  
Apr-04-22 08:00AM  
Mar-31-22 04:05PM  
Mar-05-22 07:22AM  
Feb-24-22 06:00AM  
Feb-16-22 04:05PM  
Feb-02-22 01:38PM  
Jan-27-22 08:00AM  
Dec-16-21 01:07PM  
Dec-05-21 06:39AM  
Nov-02-21 08:00AM  
Oct-11-21 08:00AM  
Sep-10-21 10:21AM  
Sep-03-21 09:00AM  
Aug-10-21 06:00AM  
Aug-09-21 08:00AM  
Jul-13-21 08:00AM  
Jun-17-21 07:00AM  
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mowry AnnaCFO and TreasurerJun 27Buy2.755,50015,12439,250Jun 28 06:17 PM
Patel Sujal MCEO, President, and SecretaryMay 09Buy3.9650,000198,0009,964,488May 10 08:28 PM
Patel Sujal MCEO, President, and SecretaryMar 04Option Exercise10.001001,0009,914,488Mar 04 05:39 PM
Patel Sujal MCEO, President, and SecretaryMar 03Buy3.6050,000179,8909,914,388Mar 04 05:39 PM
PERCEPTIVE ADVISORS LLCDirectorDec 08Buy5.36200,0001,072,0009,111,151Dec 10 04:05 PM
Posard Matthew L.DirectorDec 01Buy4.4730,000134,10550,000Dec 01 09:41 PM
Patel Sujal MCEO, President, and SecretaryDec 01Buy4.7388,022416,3979,864,388Dec 02 08:49 AM
Patel Sujal MCEO, President, and SecretaryNov 30Buy4.72161,978764,7799,776,366Dec 02 08:49 AM
Posard Matthew L.DirectorNov 30Buy4.5720,00091,40020,000Dec 01 09:41 PM
Mowry AnnaCFO and TreasurerNov 24Buy4.5815,00068,63232,500Nov 24 05:12 PM
McIlwain Matthew SDirectorNov 15Buy5.30100,000529,890459,075Nov 17 08:19 PM
McIlwain Matthew SDirectorAug 26Buy7.7111,70990,314359,075Aug 26 07:29 PM
McIlwain Matthew SDirectorAug 25Buy7.7411,69390,458347,366Aug 26 07:29 PM
McIlwain Matthew SDirectorAug 24Buy7.6813,568104,269335,673Aug 26 07:29 PM
Murphy Matthew B.General CounselAug 13Buy7.565,00037,80634,140Aug 13 09:01 PM
Mowry AnnaCFO and TreasurerAug 12Buy7.7117,500134,92517,500Aug 16 05:12 PM